about
Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertilityInsulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertilityNatural product agonists of peroxisome proliferator-activated receptor gamma (PPARĪ³): a reviewDrug-induced QT interval prolongation: does ethnicity of the thorough QT study population matter?The current role of thiazolidinediones in diabetes management.Hepatobiliary disposition of troglitazone and metabolites in rat and human sandwich-cultured hepatocytes: use of Monte Carlo simulations to assess the impact of changes in biliary excretion on troglitazone sulfate accumulation.Therapeutic interventions and oxidative stress in diabetesIdiosyncratic drug-induced liver injury and the role of inflammatory stress with an emphasis on an animal model of trovafloxacin hepatotoxicityDrug-induced liver injury due to varenicline: a case report.Effect of structural modifications on 3-(3,5-dichlorophenyl)-2,4-thiazolidinedione-induced hepatotoxicity in Fischer 344 ratsClinical perspectives on xenobiotic-induced hepatotoxicity.Cytotoxicity of 3-(3,5-dichlorophenyl)-2,4-thiazolidinedione (DCPT) and analogues in wild type and CYP3A4 stably transfected HepG2 cells.Recognizing drug-induced liver injury: current problems, possible solutions.Idiosyncratic drug hepatotoxicity.Effect of troglitazone on radiation sensitivity in cervix cancer cells.Drug-Induced Liver Injury Network (DILIN) prospective study: rationale, design and conduct.Effect of berberine on insulin resistance in women with polycystic ovary syndrome: study protocol for a randomized multicenter controlled trialPleiotropic effects of thiazolidinediones.Integrative toxicoproteomics implicates impaired mitochondrial glutathione import as an off-target effect of troglitazoneMonitoring for hepatotoxicity: what is the predictive value of liver "function" tests?Inflammatory stress and idiosyncratic hepatotoxicity: hints from animal models.Can modeling of health outcomes facilitate regulatory decision making? The benefit-risk tradeoff for rosiglitazone in 1999 vs. 2007.The safety of thiazolidinediones.Idiosyncratic reactions and metabolism of sulfur-containing drugs.Hepatotoxicity of tyrosine kinase inhibitors: clinical and regulatory perspectives.Idiosyncratic drug-induced liver injury: an update on the 2007 overview.Hepatobiliary transporters in drug-induced cholestasis: a perspective on the current identifying tools.Profiling cumulative proportional reporting ratios of drug-induced liver injury in the FDA Adverse Event Reporting System (FAERS) database.Validation of multivariate outlier detection analyses used to identify potential drug-induced liver injury in clinical trial populations.Thiazolidinedione drugs in the treatment of type 2 diabetes mellitus: past, present and future.The Promise of New Technologies to Reduce, Refine, or Replace Animal Use while Reducing Risks of Drug Induced Liver Injury in Pharmaceutical Development.Regulatory decision-making: are we getting it right?Past and current perspective on new therapeutic targets for Type-II diabetes.The hazards of rapid approval of new drugs.The Potential Return on Public Investment in Detecting Adverse Drug Effects.Telithromycin-associated hepatotoxicity: Clinical spectrum and causality assessment of 42 cases.Unintended hepatic adverse events associated with cancer chemotherapy.Using controlled clinical trials to learn more about acute drug-induced liver injury.Idiosyncratic liver injury: challenges and approaches.Evaluation of miR-122 as a Serum Biomarker for Hepatotoxicity in Investigative Rat Toxicology Studies.
P2860
Q24197673-B0DAE29B-B552-4058-8018-7117B25B1048Q24240654-AA63C38D-5895-42FD-84EF-52DA57C591C0Q24561401-9C9B3B94-7E5F-4C3A-9E6C-C9CE95995B8EQ27006580-9108873A-3069-42A7-AB8C-D80F7F78E101Q30250347-47F75C17-1FAB-4F1D-AA0C-5F1E8E735B50Q33574904-1530924A-3A3F-4255-90E2-BF227DAE5953Q33870395-22E3BBDD-007A-47D9-80C3-E96B3DBE5440Q34200596-C0F25371-6D69-4DC8-B4D0-537C4F8C84CCQ34297836-13658251-EF84-41FE-9CA6-60B04010465CQ35218115-56A16C40-FE4E-4088-99F6-C69007862AE5Q35828028-84D6E9C4-0CAA-4682-AE41-AE71F85FD53CQ36067499-2EA76D3A-D247-4F1D-B0FF-39C65CE93C6AQ36086434-6159CD34-16B6-4EBB-9583-A690E7FCD421Q36148442-4829F933-F04E-48EE-9CCD-BF54F9F8DD7DQ36195948-15134740-0D1D-4715-B518-CDBA2D6BAC32Q36799781-321F9B8C-EAE3-4F5A-A3EA-E7804261720AQ37042471-FFF06F38-8DED-43FB-B7EA-D7D0E56525D3Q37142044-AF9C4918-67B1-4EB4-BD15-21924DCF9CC8Q37247744-DD1A1617-0922-408A-BC60-FBE4BCD3977EQ37364425-F7796170-A6E2-4A64-AB23-7A59AD932EB4Q37391731-830E1072-EC36-4737-BF42-4F2DD12D3516Q37834962-37633B02-9D36-49A6-AE42-642571EF97CDQ37848841-02D58A55-B820-4C17-9AEC-A97A5538E114Q37991021-BD71DAB6-77E5-4065-B200-220B4D4D6B46Q38101884-1B99BDB6-603B-4FC6-85A7-4D13A11B7BC4Q38145274-D04C7522-5BF6-4D04-A3D0-51C32D4FAC6FQ38192698-C8A8639B-8FE8-41DC-962A-0B1A2904127AQ38423805-EDC88AE8-9EE6-4548-ABC0-82E366C6E2BCQ38430712-9BB853EB-EAEB-496D-AC4E-EA83D88968B5Q38641190-559D35BB-9E47-42EF-A5CF-B51F4F0E686AQ38774776-7E8BAC1B-AA27-4098-B056-31ED77C2F6ECQ38996482-7E8B6EAE-F4B2-4A2C-8406-925C3D3E229DQ39349756-9A80FCAD-B1E1-4C95-8584-C6516CF7CC5DQ39762702-3BF0E409-2AB5-41E5-8085-ECF7B5522F8AQ40201233-2F2B08C3-F2A8-41D3-B7AD-8366CC464A32Q40402176-0434D3EC-994A-447A-9DEA-7EAAAE2F1713Q43254477-50F1E927-2BC7-48B4-919D-F523D4DD8183Q45833400-2C9DB792-526A-4D36-B9A2-C9342C36FCD0Q45993061-A96AC052-87C9-4158-9C71-78D0BC1115DEQ46707681-1A186348-9DA4-4BB8-834A-1CF300554808
P2860
description
2003 nĆ® lÅ«n-bĆ»n
@nan
2003幓ć®č«ę
@ja
2003幓å¦ęÆęē«
@wuu
2003幓å¦ęÆęē«
@zh
2003幓å¦ęÆęē«
@zh-cn
2003幓å¦ęÆęē«
@zh-hans
2003幓å¦ęÆęē«
@zh-my
2003幓å¦ęÆęē«
@zh-sg
2003幓åøč”ęē«
@yue
2003幓åøč”ęē«
@zh-hant
name
Troglitazone-induced liver failure: a case study.
@en
Troglitazone-induced liver failure: a case study.
@nl
type
label
Troglitazone-induced liver failure: a case study.
@en
Troglitazone-induced liver failure: a case study.
@nl
prefLabel
Troglitazone-induced liver failure: a case study.
@en
Troglitazone-induced liver failure: a case study.
@nl
P2093
P1476
Troglitazone-induced liver failure: a case study.
@en
P2093
David J Graham
John R Senior
Lanh Green
Parivash Nourjah
P304
P356
10.1016/S0002-9343(02)01529-2
P407
P577
2003-03-01T00:00:00Z